Close Menu

NEW YORK – Sema4 said on Wednesday that it has signed an agreement to merge with CM Life Sciences, a special purpose acquisition company (SPAC) sponsored by affiliates of Casdin Capital and Corvex Management, with the ultimate purpose of becoming publicly traded through the company's position on the Nasdaq Global Market.

Once the transaction is complete, expected in the second quarter, CM Life Sciences will be renamed and its common stock will be listed on the Nasdaq under a name and ticker symbol that has yet to be announced.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.